CG Oncology Unveils Promising Cretostimogene Grenadenorepvec Data in High-Risk Bladder Cancer Trials

Reuters11-26

CG Oncology Unveils Promising Cretostimogene Grenadenorepvec Data in High-Risk Bladder Cancer Trials

CG Oncology Inc. has announced that new clinical results on cretostimogene grenadenorepvec, an investigational intravesical therapy for non-muscle invasive bladder cancer (NMIBC), will be presented at the Society of Urologic Oncology (SUO) 26th Annual Meeting, scheduled for December 2-5, 2025, in Phoenix, Arizona. Two late-breaking podium presentations will highlight topline results from BOND-003 Cohort P, a study in high-risk, papillary-only, BCG-unresponsive NMIBC, and first results from CORE-008 Cohort A, a phase 2 study in high-risk, BCG-naïve NMIBC with carcinoma in situ. Additionally, three posters will provide updates, including 24-month outcomes from BOND-003 Cohort C and ongoing trial progress and program designs related to cretostimogene grenadenorepvec. Results from these studies are scheduled to be presented during the SUO meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592360-en) on November 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586879409?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586879409","market":"nz","top_or_hot":-1,"title":"CG Oncology Unveils Promising Cretostimogene Grenadenorepvec Data in High-Risk Bladder Cancer Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CG Oncology Unveils Promising Cretostimogene Grenadenorepvec Data in High-Risk Bladder Cancer Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CGON\">CG Oncology Inc.</a> has announced that new clinical results on cretostimogene grenadenorepvec, an investigational intravesical therapy for non-muscle invasive bladder cancer (NMIBC), will be presented at the Society of Urologic Oncology (SUO) 26th Annual Meeting, scheduled for December 2-5, 2025, in Phoenix, Arizona. Two late-breaking podium presentations will highlight topline results from BOND-003 Cohort P, a study in high-risk, papillary-only, BCG-unresponsive NMIBC, and first results from CORE-008 Cohort A, a phase 2 study in high-risk, BCG-naïve NMIBC with carcinoma in situ. Additionally, three posters will provide updates, including 24-month outcomes from BOND-003 Cohort C and ongoing trial progress and program designs related to cretostimogene grenadenorepvec. Results from these studies are scheduled to be presented during the SUO meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592360-en) on November 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CG Oncology Unveils Promising Cretostimogene Grenadenorepvec Data in High-Risk Bladder Cancer Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCG Oncology Unveils Promising Cretostimogene Grenadenorepvec Data in High-Risk Bladder Cancer Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-26 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CG Oncology Unveils Promising Cretostimogene Grenadenorepvec Data in High-Risk Bladder Cancer Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CGON\">CG Oncology Inc.</a> has announced that new clinical results on cretostimogene grenadenorepvec, an investigational intravesical therapy for non-muscle invasive bladder cancer (NMIBC), will be presented at the Society of Urologic Oncology (SUO) 26th Annual Meeting, scheduled for December 2-5, 2025, in Phoenix, Arizona. Two late-breaking podium presentations will highlight topline results from BOND-003 Cohort P, a study in high-risk, papillary-only, BCG-unresponsive NMIBC, and first results from CORE-008 Cohort A, a phase 2 study in high-risk, BCG-naïve NMIBC with carcinoma in situ. Additionally, three posters will provide updates, including 24-month outcomes from BOND-003 Cohort C and ongoing trial progress and program designs related to cretostimogene grenadenorepvec. Results from these studies are scheduled to be presented during the SUO meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592360-en) on November 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL6c7cL1:1","article_id":"2586879409","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586879409","pubTimestamp":1764104730,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CG Oncology Inc. has announced that new clinical results on cretostimogene grenadenorepvec, an investigational intravesical therapy for non-muscle invasive bladder cancer , will be presented at the Society of Urologic Oncology  26th Annual Meeting, scheduled for December 2-5, 2025, in Phoenix, Arizona. Two late-breaking podium presentations will highlight topline results from BOND-003 Cohort P, a study in high-risk, papillary-only, BCG-unresponsive NMIBC, and first results from CORE-008 Cohort A, a phase 2 study in high-risk, BCG-nave NMIBC with carcinoma in situ. Additionally, three posters will provide updates, including 24-month outcomes from BOND-003 Cohort C and ongoing trial progress and program designs related to cretostimogene grenadenorepvec. Results from these studies are scheduled to be presented during the SUO meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","CGON":"CG Oncology Inc.","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据"},"translate_title":"CG Oncology公布了高危膀胱癌试验中有希望的Cretostimogene Grenadenorepvec数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"CGON":0.9},"content_text":"CG Oncology Unveils Promising Cretostimogene Grenadenorepvec Data in High-Risk Bladder Cancer Trials\n    \n\nCG Oncology Inc. has announced that new clinical results on cretostimogene grenadenorepvec, an investigational intravesical therapy for non-muscle invasive bladder cancer (NMIBC), will be presented at the Society of Urologic Oncology (SUO) 26th Annual Meeting, scheduled for December 2-5, 2025, in Phoenix, Arizona. Two late-breaking podium presentations will highlight topline results from BOND-003 Cohort P, a study in high-risk, papillary-only, BCG-unresponsive NMIBC, and first results from CORE-008 Cohort A, a phase 2 study in high-risk, BCG-naïve NMIBC with carcinoma in situ. Additionally, three posters will provide updates, including 24-month outcomes from BOND-003 Cohort C and ongoing trial progress and program designs related to cretostimogene grenadenorepvec. Results from these studies are scheduled to be presented during the SUO meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592360-en) on November 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586879409","isCrawlerRequest":true}